| Texto completo | |
| Autor(es): |
Pernomian, Larissa
[1]
;
do Prado, Alejandro F.
[2]
;
Gomes, Mayara S.
[3]
;
Pernomian, Laena
[2]
;
da Silva, Carlos H. T. P.
[1]
;
Gerlach, Raquel F.
[4]
;
de Oliveira, Ana M.
[3]
Número total de Autores: 7
|
| Afiliação do(s) autor(es): | [1] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto FCFRP, Dept Pharmaceut Sci, BR-14049 Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pharmacol, Ribeirao Preto, SP - Brazil
[3] Univ Sao Paulo, FCFRP, Dept Chem & Phys, Ribeirao Preto, SP - Brazil
[4] Univ Sao Paulo, Fac Odontol Ribeirao Preto FORP, Dept Morphol, Ribeirao Preto, SP - Brazil
Número total de Afiliações: 4
|
| Tipo de documento: | Artigo Científico |
| Fonte: | European Journal of Pharmacology; v. 764, p. 173-188, OCT 5 2015. |
| Citações Web of Science: | 11 |
| Resumo | |
AT(1) antagonists effectively prevent atherosclerosis since AT(1) upregulation and angiotensin II-induced proinflammatory actions are critical to atherogenesis. Despite the classic mechanisms underlying the vasoprotective and atheroprotective actions of AT(1) antagonists, the cross talk between angiotensin-converting enzyme-angiotensin II-AT(1) and angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axes suggests other mechanisms beyond AT1. blockage in such effects. For instance, angiotensin-converting enzyme 2 activity is inhibited by reactive oxygen species derived from AT(1)-mediated proinflammatory signaling. Since angiotensin-(1-7) promotes antiatherogenic effects, we hypothesized that the vasoprotective and atheroprotective effects of AT(1) antagonists could result from their inhibitory effects on the AT(1)-mediated negative modulation of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality, interestingly, our results showed that early atherosclerosis triggered in thoracic aorta from high cholesterol fed-Apolipoprotein E-deficient mice impairs angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis functionality by a prointlammatory-redox AT(1)-mediated pathway, in such mechanism, AT(1) activation leads to the aortic release of tumor necrosis factor-alpha which stimulates NAD(P)H oxidase/Nox1-driven generation of superoxide and hydrogen peroxide. While hydrogen peroxide inhibits angiotensin-converting enzyme 2 activity, superoxide impairs MAS functionality. Candesartan treatment restored the functionality of angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis by inhibiting the proinflammatory-redox AT(1)-mediated mechanism. Candesartan also promoted vasoprotective and atheroprotective effects that were mediated by MAS since A779 (MAS antagonist) co-treatment inhibited them. The role of MAS receptors as the final mediators of the vasoprotective and atheroprotective effects of candesartan was supported by the vascular actions of angiotensin-(1-7) upon the recovery of the functionality of vascular angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis. (C) 2015 Elsevier B.V. All rights reserved. (AU) | |
| Processo FAPESP: | 14/17740-0 - Planejamento, desenvolvimento e avaliação farmacológica de novos antagonistas de receptores para hidrocarbonetos arila (AhR) candidatos a fármacos ateroprotetores |
| Beneficiário: | Larissa Pernomian |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |
| Processo FAPESP: | 13/08216-2 - CPDI - Centro de Pesquisa em Doenças Inflamatórias |
| Beneficiário: | Fernando de Queiroz Cunha |
| Modalidade de apoio: | Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs |
| Processo FAPESP: | 12/00640-7 - Estudo das consequências do processo inflamatório induzido por receptores AT1 durante aterosclerose sobre o eixo ECA2 - angiotensina-(1-7) -Mas em aorta de camundongo e da participação de receptores Mas nos efeitos vaso- e ateroprotetores de losartan |
| Beneficiário: | Larissa Pernomian |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |
| Processo FAPESP: | 12/09019-3 - Consequências da dislipidemia sobre os eixos ECA - Ang II - AT1 e ECA2 - Ang-(1-7) - mas do sistema angiotensinérgico em aorta de camundongos LDLr knockout jovens e adultos |
| Beneficiário: | Ana Maria de Oliveira |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |